Search Results 1941-1950 of 16015 for Epilepsy (Partial Onset)

  1. Science Saturday: Arresting melanoma's molecular drivers - Mayo Clinic News Network

    ... early detection and treatment of this aggressive disease. ... 'Early' means ... (VIDEO) When seizures don't stop: The battle against drug-resistant epilepsy.

  2. Catching up: More COVID-19 questions and answers - Mayo Clinic News Network

    Now, that's speculation and it's very early. It ... (VIDEO) When seizures don't stop: The battle against drug-resistant epilepsy ... epilepsy · About the ...

  3. Mayo Clinic Board Recognizes Retiring Members, Elects New Members

    (VIDEO) When seizures don't stop: The battle against drug-resistant epilepsy. News Releases. Mayo Clinic researchers lead transformative shift toward ...

  4. Headache: First aid - Mayo Clinic

    Causes mental confusion or loss of consciousness. Happens with seizures. Immediate medical attention also is needed if your headache occurs with new: Dizziness ...

  5. SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients - Mayo Clinic

    ... duration of response (Part A and B). - To assess the relationship between clinical effects (adverse event [AE] and/or tumor response) and CD38 receptor ...

  6. Funding - Aspirin-Exacerbated Respiratory Disease: Elina Jerschow - Mayo Clinic Research

    Investigator & Role, Grant Title, Funding Source, Duration. Elina Jerschow, M.D., M.S., principal investigator; Douglas G. Brownfield, Ph.D., co-principal ...

  7. Projects - Genetics of Alzheimer's Disease and Endophenotypes Laboratory - Mayo Clinic Research

    The goal is to identify and characterize novel genes, transcripts and genetic risk variants for late-onset Alzheimer's disease. Gene Expression Studies in ...

  8. A Study to Evaluate EAA181 to Treat Newly-diagnosed Multiple Myeloma - Mayo Clinic

    About this study. The primary purpose of this study is to determine if bortezomib, daratumumab, lenalidomide and dexamethasone (Btz-DRd) consolidation ...

  9. A Study to Evaluate MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Documented ALS history of location of disease onset (i.e., bulbar onset, limb onset). A total ALSFRS-R score of at least 35 overall at screening and: No ...

  10. A Study to Evaluate ALZT-OP1a in Subjects with Mild-to-Moderate Amyotrophic Lateral Sclerosis - Mayo Clinic

    Disease duration from ALS symptom onset of motor weakness ≤ 24 months. ALSFRS-R total score ≥ 36 at screening visit. ALSFRS-R Breathing sub-score should ...